Covid-19, Virus Disease
Conditions
Brief summary
The overall goal is to study the immune response to SARS-CoV-2 infection over the period of one year in the blood of a representative cohort of ETH students/employees.
Interventions
None listed
Sponsors
Goldhahn Jörg
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* ETH employee or ETH student and their family members living in the same household at the start of the study * Between 18 and 64 years of age at the start of the study * Signed informed consent
Exclusion criteria
* Age over 64 years at the start of the study * In quarantine or self-confinement at the start of the study * Active COVID-19 infection at the start of the study: * Diagnosed with a laboratory test * Suspected based on typical symptoms such as fever (\>38°C), acute pulmonary ex-acerbation or sudden loss of gustatory taste * The following medical condition * With continuous steroid therapy/ chemotherapy/immunsuppressive therapy * In treatment for cancer * With severe autoimmune disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seroprevalence as well as the titer of serum antibodies (IgM, IgG and IgA) targeting SARS-CoV-2 antigens | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| the property of peripheral blood mononuclear cells before and after an infection with SARS-CoV-2 as opposed to other pathogens | 12 months |
| the property of IgM and IgA antibody titers against the nucleocapsid protein of SARS-CoV-2 in symptomatic as well as asymptomatic COVID-19 infections over the course of time following an infection | 12 months |
| the immune response to common-cold (corona)virus and influenza virus infections in patients with COVID-19 infections | 12 months |
Countries
Switzerland
Outcome results
None listed